Posters

Efficacy of bromfenac 0.9 mg/ml ophthalmic solution for preventing pseudophakic cystoid macular edema

Poster Details

First Author: E.Stangogianni Druya GREECE

Co Author(s):    C. Stangogianni                    

Abstract Details

Purpose:

To determine the efficacy of Bromfenac ophthalmic solutions 0.9 mg/ml as unique non steroidal anti-inflammatory therapy in prevention of cystoid macular edema following cataract surgery.

Setting:

LASERLENS. ONE DAY CLINIC. IOANNINA-GREECE

Methods:

Prospective, descriptive and interventional study. It includes 100 eyes of 100 patients that required phacoemulsification and with uncomplicated cataract surgery. Bromfenac dosed was twice daily beginning one day prior ocular surgery and continuing through the thirty days of the postoperative period. Ocular pain was scored on a 4-point scale (0 none; 4 severe). On slit lamp examination, aqueous cells and aqueous flare were scored on a 3-point scale. On day 30 and 90 optical coherent tomography was carried out in order to dismiss the presence of cystoid macular edema (CME), retinal fluorescent angiography only to confirm the CME.

Results:

An adequate non steroidal anti-inflammatory response was observed using the Bromfenac as unique therapy in patients with uncomplicated cataract surgery. Also we found an important reduction in the incidence of CME and of the subclinical edema with it’s topical administration.

Conclusions:

The use of Bromfenac after cataract surgery is effective for the prevention of the pseudophakic cystoid  macular edema, for the management of postoperative inflammation and for the pain following cataract surgery.

Financial Disclosure:

None